[Anticholesteremic agents in children]

Related Experiment Video

Updated: Sep 23, 2026

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Jean-Philippe Girardet1

  • 1Service de Gastro-Entérologie et de Nutrition Pédiatriques, Hôpital Armand-Trousseau, Paris, France. jean-philippe.girardet@trs.ap-hop-paris.fr

Therapie
|June 26, 2003
PubMed

Insights

Cholesterol-lowering drugs are recommended for children with genetic high cholesterol conditions if diet fails. Bile acid-binding resins are the first choice, with statins an option for older children.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Disease Prevention
  • Pharmacology

Context:

  • Hypercholesterolemia in children is a key factor in preventing adult-onset coronary heart disease.
  • Genetic dyslipidemias like familial hypercholesterolemia necessitate early intervention.
  • High LDL-cholesterol levels in children with genetic conditions pose significant cardiovascular risks.

Purpose:

  • To outline the appropriate use of cholesterol-lowering medications in pediatric patients.
  • To define treatment thresholds for pharmacotherapy in children with inherited hypercholesterolemia.
  • To review the safety and efficacy profiles of available drug classes for pediatric use.

Summary:

  • Pharmacological treatment for hypercholesterolemia in children is indicated for hereditary conditions when LDL-cholesterol remains above 190 mg/dL after 6 months of diet.
  • Bile acid-binding resins (colestyramine) are the primary choice due to established efficacy and safety in children.
  • HMG-CoA reductase inhibitors (statins) may be used in children over 8-9 years old if adherence to resins is poor, though long-term safety is not fully known.
  • Fibrates are effective but lack sufficient safety data from controlled pediatric studies.

Impact:

  • Provides guidance for clinicians on managing pediatric hypercholesterolemia.
  • Highlights the importance of early intervention for genetic lipid disorders.
  • Informs treatment decisions regarding the selection and sequencing of lipid-lowering therapies in children.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...